[Current indications for triple therapy in hepatitis C virus infection]. / Indicaciones actuales de tratamiento triple para la hepatitis C.
Gastroenterol Hepatol
; 35(4): 266-77, 2012 Apr.
Article
em Es
| MEDLINE
| ID: mdl-22410706
ABSTRACT
Chronic hepatitis C virus (HCV) infection is the main cause of liver cirrhosis and liver carcinoma in western countries. There is evidence that HCV clearance induced by antiviral therapy is beneficial, increasing survival and reducing the complications of cirrhosis. Triple therapy with boceprevir or telaprevir associated with pegylated interferon and ribavirin has increased rates of sustained viral response both in treatment-naïve patients and in those failing previous regimens. Before treating patients with these new molecules, physicians should be familiar with their indications and the regimens to be used. Furthermore, both adverse events and the development of resistances must be monitored. The main aims are careful selection of patients and of the regimen to be used, and achieving adequate adherence to obtain optimal results.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Hepatite C Crônica
Limite:
Humans
Idioma:
Es
Ano de publicação:
2012
Tipo de documento:
Article